المؤلفون: Matthew Martin, Katrin Beyer, Juan Luis Pérez-Navero, Eduardo López-Laso, Matias Mora, L. González Gutierrez-Solana, J. Martínez-Ruiz, J. Hernandez-Vara, M. Llorente, Á. García Cazorla, Juan-Luis Ramos, Rafael Artuch, María José de la Torre-Aguilar, J. Serrano Cárdenas, Pablo Mir, Beatriz Quintáns, M.J. Sobrido Gómez, A. Adarmes, J.J. Ochoa Sepúlveda, M.D. Teva, C. Castaño-de la Mota, J.C. Gómez-Esteban, Joaquín A. Fernández-Ramos, E. Moreno-Medinilla

المصدر: Parkinsonism & Related Disorders. 94:67-78

مصطلحات موضوعية: GTPCH, Pediatrics, medicine.medical_specialty, Levodopa, Dopamine, Parkinson's disease, Decarboxylase inhibitor, Pedigree chart, Disease, Autosomal dominant Segawa disease, Parkinsonism, medicine, Humans, Founder mutation, GTP Cyclohydrolase, Adverse effect, Retrospective Studies, Dystonia, Dyskinesias, business.industry, medicine.disease, Dopa-responsive dystonia, Autosomal dominant GTPCH deficiency, Treatment Outcome, Neurology, Dystonic Disorders, Spain, Cohort, Neurology (clinical), Geriatrics and Gerontology, business, GCH1, Founder effect, medicine.drug

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::75a8c227ec6aa98459dbd98688830544
https://doi.org/10.1016/j.parkreldis.2021.11.014